Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes

Inclusion Criteria: * Healthy volunteers, both sex, aging 18 to 45 years; * Availability for all procedures during the study period; * Provide free informed consent to join the study Exclusion Criteria: * Diagnosis of concomitant infections or diseases that might affect immunity, including active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasias, and autoimmune diseases; * Previous or current diagnosis or family antecedent of rheumatic fever, chorea, obsessive-compulsive disorder or glomerulonephritis; * Previous or current diagnosis of cardiac disease; * Severe asma or Chronic obstructive pulmonary disease (COPD); * Abnormal neurological clinical assessment, particularly chorea; * Use of treatments that might affect the immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use equal or longer than two weeks), or antineoplastic agents; * Use of treatments that might affect heart valves in the latest four weeks, including fenfluramine e dexfenfluramine; * Kidney failure determined by creatinine clearance lower than 45 ml/min/1,73m²; * History of intolerance or allergy to any component of investigational products, including antigen or adjuvant; * Presence of abnormalities in heart valves or heart anatomy defined by echocardiogram; * Electrocardiogram disturbances; * Presence of cross-reactive antibodies against human tissues (heart, kidney, cartilage, brain) in screening tests; * Evidence or suspicion of recent infection due to S. pyogenes assessed by clinical symptoms and negative rapid test for Streptococcus; * Pregnancy, breastfeeding mother or intention to became pregnant during the study period; * Any other condition that might affect the study process according to the investigators.